Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

We previously reported improved pathologic complete response (pCR) in a prospective phase II study using neoadjuvant bevacizumab in combination with chemotherapy compared to chemotherapy alone in breast cancer patients (41% vs. 25%, p = 0.0291). In this study, we queried germline single-nucleotide p...

Full description

Bibliographic Details
Main Authors: Issam Makhoul, Valentina K Todorova, Eric R Siegel, Stephen W Erickson, Ishwori Dhakal, Vinay R Raj, Jeannette Y Lee, Mohammed S Orloff, Robert J Griffin, Ronda S Henry-Tillman, Suzanne Klimberg, Laura F Hutchins, Susan A Kadlubar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5207665?pdf=render

Similar Items

Similar Items